View ValuationAcarix 향후 성장Future 기준 점검 5/6Acarix (는) 각각 연간 109.9% 및 68.8% 수익과 수익이 증가할 것으로 예상됩니다.핵심 정보109.9%이익 성장률n/aEPS 성장률Medical Equipment 이익 성장16.1%매출 성장률68.8%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트19 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Feb 13Acarix AB (publ), Annual General Meeting, May 13, 2026Acarix AB (publ), Annual General Meeting, May 13, 2026.공시 • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q4, 2026 Results on Feb 11, 2027Acarix AB (publ) announced that they will report Q4, 2026 results on Feb 11, 2027공시 • Jun 26Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor®? System in U.S. Emergency DepartmentsAcarix announced the publication of a new peer-reviewed study in PharmacoEconomics - Open demonstrating that the CADScor®? System is a cost-effective diagnostic tool for evaluating low-risk chest pain patients in U.S. emergency departments. The independent study, conducted by researchers from the Baim Institute for Clinical Research and leading academic hospitals in Boston, utilized a comprehensive economic model to compare the CADScor®? system with traditional noninvasive cardiac imaging methods. Results showed that a "CADScor-First" strategy could lead to substantial cost savings-estimated between $7.3 million and $15.3 million per 10,000 patients-without compromising patient safety. The CADScor®? System are FDA-cleared and uses advanced high fidelity acoustics and proprietary algorithms to assess the risk of obstructive coronary artery disease in under 10 minutes at the point of care.공시 • May 14Acarix AB (Publ) Approves Election of Jan Poulsen as Director and Chair of the BoardAcarix AB (publ) announced that at its AGM held on 13 May 2025, the shareholders approved election of Jan Poulsen as new director. Jan Poulsen was elected as chair of the board.공시 • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q1, 2025 Results on May 12, 2025Acarix AB (publ) announced that they will report Q1, 2025 results on May 12, 2025공시 • Nov 12Acarix AB (publ), Annual General Meeting, May 15, 2025Acarix AB (publ), Annual General Meeting, May 15, 2025. Location: stockholm Sweden공시 • Aug 13Acarix Expands Within US Wellness Exam MarketAcarix announced expanded use of the CADScor System within wellness exams as part of self-insured companies' health plans. As healthcare costs continue to rise, the CADScor System has now been proven to be an easy and quick strategy to risk stratify patients for significant coronary artery disease. The US employer self-insured market is rapidly expanding to include approximately 60 million Americans. In a self-funded insurance plan, companies bear the direct financial responsibility for their employee's healthcare costs and are acutely aware of the impact that serious health events, such as heart attacks, can have on their bottom line. Acarix has expanded its presence in the self-insured healthcare market, focusing on providing solutions for wellness exams. The first strategic account was signed with Delaware Resource Group, which successfully assessed its employees and families with the CADScor System.공시 • Jul 05Acarix AB (publ) announced that it expects to receive SEK 21 million in fundingAcarix AB (publ) announced a private placement to issue 60,000,000 common shares at an issue price of SEK 0.35 per share for the gross proceeds of SEK 21,000,000 on July 3, 2024.공시 • Jun 13Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation StudyAcarix announced the enrollment of the first patient in its first US-based clinical study. The study aims to gather real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States. The study is set to enroll 200 patients at the University of California, Davis, assessing the potential improvements in cost-effectiveness, time savings, and reduction in side effects by using the CADScor System compared to traditional stress imaging tests. This marks a crucial step in enhancing the understanding of the CADScor System's role in various clinical workflows across the United States.공시 • May 29Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024Acarix AB (publ) announced appointment of Jeff Thomas as the new Head of US Sales, effective June 1st, 2024. With over two decades of sales experience in the medical device and healthcare industries, Thomas brings outstanding expertise and leadership to his new role, setting the stage for exciting new developments at Acarix. Throughout his career, Thomas has consistently delivered exceptional results, both in Fortune 100 companies and start-ups. His deep understanding of market trends in the healthcare sector, particularly in cardiovascular therapy, positions him as a strategic asset for Acarix. Thomas' broad experience at Biotronik Inc., St. Jude Medical, Guidant Corp. (now Boston Scientific), and other leading MedTech companies highlights his exceptional performance, leadership, and commitment to improving patient outcomes. Prior to joining Acarix, Thomas served as the Executive VP of Sales & Business Development at Vitalus Health, where he led all aspects of sales strategy, resulting in significant revenue growth and the expansion of the customer base. His achievements include developing and implementing revenue growth strategies, fostering a high-performance culture, and building key stakeholder relationships.공시 • May 15Acarix AB (publ) Approves Board ElectionsAcarix AB (publ) at its AGM held on May 14, 2024 approved election of Ken Nelson and Dr. Tony Das as new directors.공시 • Apr 11Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation StudyAcarix AB announced the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States. The clinical study will collect data from 200 patients at the University of California, Davis, being assessed for chest pain in both the emergency department and outpatient cardiology clinic. The study will assess the potential improvement in cost-effectiveness, time savings, and reduction in side effects by utilizing the CADScor System to identify non-obstructive coronary artery disease in chest pain patients compared to traditional stress imaging tests. Patient enrollment for the study will commence in early Second Quarter 2024, marking a crucial step forward in advancing the understanding of the CADScor System in various clinical workflows in the United States.공시 • Feb 15Acarix Appoints New Members to the Advisory BoardAcarix announced the appointment of three new advisors to its team. Joining the advisory board are Ken Nelson, known for his leadership in the MedTech space; Dr. Saumil R. Oza, MD, an experienced electrophysiologist from Ascension Medical Group; and Dave Braun, a strategic and customer-driven executive with over 40 years of experience working in startup and large company environments. Ken Nelson brings over two decades of experience in the digital health, medical device, and remote patient monitoring industries. As a partner in the Medtech Advantage Fund and Chairman of the Board for CardiaCare, Mr. Nelson has played pivotal roles in numerous disruptive cardiac digital health and MedTech startups worldwide. His track record includes leadership positions in top market share players such as BioTelemetry, iRhythm, and Bardy Diagnostics. Dr. Saumil R. Oza, MD, is an electrophysiologist practicing in Jacksonville, FL, with over 15 years of experience and numerous publications. Renowned as a national expert in cardiology, Dr. Oza serves on advisory boards for established companies like Boston Scientific, Johnson and Johnson, GE, and Novo Nordisk, as well as biotech startups. His clinical and business expertise will provide the Acarix team with a fresh new viewpoint of the U.S. market. Dave Braun, a strategic, customer-driven entrepreneur with over four decades of leadership experience, joins Acarix as an advisor. His extensive background in strategic business planning, mergers and acquisitions, banking and investor relations, organization development, and team building will bring a fresh perspective to operational strategies. Adding these three advisors emphasizes Acarix's commitment to driving innovation in cardiac health while expanding its reach in the United States. The new advisory board members will enhance efforts to develop solutions that improve patient outcomes and advance the standard of care in cardiac diagnostics.공시 • Feb 02Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million. Security Name: Shares Security Type: Common Stock Securities Offered: 181,005,581 Price\Range: SEK 0.186공시 • Feb 01Acarix AB (publ) Announces CEO ChangesThe Board of Acarix AB (publ) announced the appointment of Aamir Mahmood as new CEO with immediate effect, starting February 1, 2024. Mr. Mahmood succeeds Acting CEO Fred Colen as well as Helen Ljungdahl Round who has decided not to return to her position later in 2024. Aamir Mahmood has more than twenty years of experience in corporate leadership in the medical device industry with a successful track record of Global commercial roles in cardiovascular device markets, including sales, marketing and strategy functions at LivaNova, Boston Scientific, and Merck. Aamir presently serves as General Manager/Vice President Americas of MicroPort CRM. MicroPort is an industry leader in the field of pacemakers and other cardiac devices used for diagnosis, treatment and management of heart rhythm disorders and heart failure. Prior to running the Americas for MicroPort, Aamir rotated through two Ex Pat assignments in Europe running Global Sales followed by Global Marketing & Strategy. Aamir has an MBA and is a member of Young Presidents’ Organization (YPO). Aamir succeeds Helen Ljungdahl Round who was appointed CEO of Acarix in January of 2022. Under Helen’s leadership Acarix established a subsidiary and commercial team in the US market, secured key commercial contracts with the Veterans Affairs Health Administration, published a clinical framework for use of the CADScor System in collaboration with the American College of Cardiology (ACC), and raised growth capital from a broad base of investors to enable further market expansion. Aamir Mahmood assumed the CEO position on February 1, 2024.공시 • Dec 15+ 5 more updatesAcarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024Acarix AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024공시 • Nov 24Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare NetworkAcarix AB (publ) announced an advancement in the utilization of its CADScor System within the Veterans Administration (VA) Healthcare network. The Southeast Louisiana VA Healthcare System has reordered CADScor Patches in their Slidell and Baton Rouge locations to be used with the CADScor System for risk-stratification of symptomatic patients suspected of coronary artery disease (CAD) throughout various facilities within their system. The Southeast Louisiana VA Healthcare System was the first VA location to place orders for CADScor System and patches in February, with approval of the CADScor System into their Standard Operating Procedure (SOP) in August. Since integrating the CADScor System into their SOP, the Southeast Louisiana VA Team has also aligned their Computerized Patient Record System (CPRS) with the SOP to ensure all relevant symptomatic patients suspected of CAD undergo a CADScor System Test. In the past few months, the Acarix team has collaborated closely with the Southeast Louisiana VA Leadership Team, providing support to more than 100 Healthcare Professionals (HCPs) through various activities, including CADScor System in-servicing within their Cardiology group. Furthermore, the team has been actively engaged in monthly Primary Care meetings with the Chief of Cardiology, effectively developing awareness about the CADScor System.공시 • Oct 19Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 90,573,602 Price\Range: SEK 0.6 Transaction Features: Rights Offering공시 • Aug 29Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical AdvisorAcarix AB (publ) announced the appointment of Dr. Deepak R. Talreja, MD, as new Medical Advisor. With an impressive background in cardiology, Dr. Talreja brings a wealth of knowledge and expertise to Acarix, further strengthening the company's commitment to transforming early cardiac diagnostics through cutting-edge acoustic and AI-based technology. As a highly respected cardiologist expert, Dr. Talreja has been at the forefront of numerous groundbreaking research initiatives, pioneering advancements that have significantly impacted patient care and outcomes. He is a graduate of the University of Virginia School of Medicine, completed his Internship and Residency at Vanderbilt University Medical Center, and fellowship at the Mayo School of Medicine. Dr. Talreja is board certified by the American Board of Internal Medicine (ABIM) in cardiovascular disease, interventional cardiology, and internal medicine: He is currently the Medical Director of the Cardiovascular Service Line at Sentara Health. Dr. Talreja's vast experience and leadership experience in cardiac electrical system procedures, interventional cardiac procedures, heart conditions and overall cardiac patient care align very well with Acarix's mission to develop patient-focused innovative solutions that address some of the challenges in early cardiac healthcare.공시 • May 12Acarix AB Elects Mikael Thorén as DirectorAcarix AB elected Mikael Thorén as new director at the AGM held on May 11, 2023.공시 • Feb 17Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023Acarix AB (publ) announced that they will report fiscal year 2022 final results on Apr 20, 2023공시 • Feb 16+ 3 more updatesAcarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024Acarix AB (publ) announced that they will report Q4, 2023 results on Feb 15, 2024공시 • Feb 14Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023Acarix AB (publ) announced that they will report Q4, 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023이익 및 매출 성장 예측OTCPK:ACIX.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202814555N/AN/A112/31/2027702N/A-15112/31/202619-29N/A-1113/31/20268-43-25-24N/A12/31/20257-48-38-37N/A9/30/20257-52-49-48N/A6/30/20256-62-55-54N/A3/31/20256-65-57-57N/A12/31/20246-66-64-63N/A9/30/20246-72-70-69N/A6/30/20246-71-73-73N/A3/31/20246-76-79-79N/A12/31/20236-78-81-81N/A9/30/20237-78-77-77N/A6/30/20236-82-82-82N/A3/31/20236-79-80-79N/A12/31/20226-77-75-75N/A9/30/20225-71-70-70N/A6/30/20225-60-59-58N/A3/31/20224-55-55-55N/A12/31/20214-52-48-48N/A9/30/20214-47-47-47N/A6/30/20213-45-44-44N/A3/31/20213-42-37-37N/A12/31/20202-41-37-37N/A9/30/20202-40-32-32N/A6/30/20201-43-37-37N/A3/31/20202-44-40-40N/A12/31/20192-46N/A-45N/A9/30/20191-48N/A-45N/A6/30/20192-50N/A-45N/A3/31/20191-47N/A-42N/A12/31/20181-42N/A-39N/A9/30/20181-43N/A-36N/A6/30/20181-37N/A-32N/A3/31/20181-34N/A-34N/A12/31/20171-30N/A-41N/A9/30/20170-32N/A-36N/A6/30/20170-55N/A-33N/A3/31/2017N/A-50N/A-24N/A12/31/2016N/A-48N/A-9N/A9/30/2016N/A-35N/A-5N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ACIX.F 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: ACIX.F (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: ACIX.F 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: ACIX.F 의 수익(연간 68.8%)이 US 시장(연간 11.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: ACIX.F 의 수익(연간 68.8%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ACIX.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 23:02종가2026/05/15 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Acarix AB (publ)는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관John SavinEdison Investment ResearchLudvig SvenssonRedeyeFilip EinarssonRedeye1명의 분석가 더 보기
공시 • Feb 13Acarix AB (publ), Annual General Meeting, May 13, 2026Acarix AB (publ), Annual General Meeting, May 13, 2026.
공시 • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q4, 2026 Results on Feb 11, 2027Acarix AB (publ) announced that they will report Q4, 2026 results on Feb 11, 2027
공시 • Jun 26Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor®? System in U.S. Emergency DepartmentsAcarix announced the publication of a new peer-reviewed study in PharmacoEconomics - Open demonstrating that the CADScor®? System is a cost-effective diagnostic tool for evaluating low-risk chest pain patients in U.S. emergency departments. The independent study, conducted by researchers from the Baim Institute for Clinical Research and leading academic hospitals in Boston, utilized a comprehensive economic model to compare the CADScor®? system with traditional noninvasive cardiac imaging methods. Results showed that a "CADScor-First" strategy could lead to substantial cost savings-estimated between $7.3 million and $15.3 million per 10,000 patients-without compromising patient safety. The CADScor®? System are FDA-cleared and uses advanced high fidelity acoustics and proprietary algorithms to assess the risk of obstructive coronary artery disease in under 10 minutes at the point of care.
공시 • May 14Acarix AB (Publ) Approves Election of Jan Poulsen as Director and Chair of the BoardAcarix AB (publ) announced that at its AGM held on 13 May 2025, the shareholders approved election of Jan Poulsen as new director. Jan Poulsen was elected as chair of the board.
공시 • Jan 29+ 4 more updatesAcarix AB (publ) to Report Q1, 2025 Results on May 12, 2025Acarix AB (publ) announced that they will report Q1, 2025 results on May 12, 2025
공시 • Nov 12Acarix AB (publ), Annual General Meeting, May 15, 2025Acarix AB (publ), Annual General Meeting, May 15, 2025. Location: stockholm Sweden
공시 • Aug 13Acarix Expands Within US Wellness Exam MarketAcarix announced expanded use of the CADScor System within wellness exams as part of self-insured companies' health plans. As healthcare costs continue to rise, the CADScor System has now been proven to be an easy and quick strategy to risk stratify patients for significant coronary artery disease. The US employer self-insured market is rapidly expanding to include approximately 60 million Americans. In a self-funded insurance plan, companies bear the direct financial responsibility for their employee's healthcare costs and are acutely aware of the impact that serious health events, such as heart attacks, can have on their bottom line. Acarix has expanded its presence in the self-insured healthcare market, focusing on providing solutions for wellness exams. The first strategic account was signed with Delaware Resource Group, which successfully assessed its employees and families with the CADScor System.
공시 • Jul 05Acarix AB (publ) announced that it expects to receive SEK 21 million in fundingAcarix AB (publ) announced a private placement to issue 60,000,000 common shares at an issue price of SEK 0.35 per share for the gross proceeds of SEK 21,000,000 on July 3, 2024.
공시 • Jun 13Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation StudyAcarix announced the enrollment of the first patient in its first US-based clinical study. The study aims to gather real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States. The study is set to enroll 200 patients at the University of California, Davis, assessing the potential improvements in cost-effectiveness, time savings, and reduction in side effects by using the CADScor System compared to traditional stress imaging tests. This marks a crucial step in enhancing the understanding of the CADScor System's role in various clinical workflows across the United States.
공시 • May 29Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024Acarix AB (publ) announced appointment of Jeff Thomas as the new Head of US Sales, effective June 1st, 2024. With over two decades of sales experience in the medical device and healthcare industries, Thomas brings outstanding expertise and leadership to his new role, setting the stage for exciting new developments at Acarix. Throughout his career, Thomas has consistently delivered exceptional results, both in Fortune 100 companies and start-ups. His deep understanding of market trends in the healthcare sector, particularly in cardiovascular therapy, positions him as a strategic asset for Acarix. Thomas' broad experience at Biotronik Inc., St. Jude Medical, Guidant Corp. (now Boston Scientific), and other leading MedTech companies highlights his exceptional performance, leadership, and commitment to improving patient outcomes. Prior to joining Acarix, Thomas served as the Executive VP of Sales & Business Development at Vitalus Health, where he led all aspects of sales strategy, resulting in significant revenue growth and the expansion of the customer base. His achievements include developing and implementing revenue growth strategies, fostering a high-performance culture, and building key stakeholder relationships.
공시 • May 15Acarix AB (publ) Approves Board ElectionsAcarix AB (publ) at its AGM held on May 14, 2024 approved election of Ken Nelson and Dr. Tony Das as new directors.
공시 • Apr 11Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation StudyAcarix AB announced the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States. The clinical study will collect data from 200 patients at the University of California, Davis, being assessed for chest pain in both the emergency department and outpatient cardiology clinic. The study will assess the potential improvement in cost-effectiveness, time savings, and reduction in side effects by utilizing the CADScor System to identify non-obstructive coronary artery disease in chest pain patients compared to traditional stress imaging tests. Patient enrollment for the study will commence in early Second Quarter 2024, marking a crucial step forward in advancing the understanding of the CADScor System in various clinical workflows in the United States.
공시 • Feb 15Acarix Appoints New Members to the Advisory BoardAcarix announced the appointment of three new advisors to its team. Joining the advisory board are Ken Nelson, known for his leadership in the MedTech space; Dr. Saumil R. Oza, MD, an experienced electrophysiologist from Ascension Medical Group; and Dave Braun, a strategic and customer-driven executive with over 40 years of experience working in startup and large company environments. Ken Nelson brings over two decades of experience in the digital health, medical device, and remote patient monitoring industries. As a partner in the Medtech Advantage Fund and Chairman of the Board for CardiaCare, Mr. Nelson has played pivotal roles in numerous disruptive cardiac digital health and MedTech startups worldwide. His track record includes leadership positions in top market share players such as BioTelemetry, iRhythm, and Bardy Diagnostics. Dr. Saumil R. Oza, MD, is an electrophysiologist practicing in Jacksonville, FL, with over 15 years of experience and numerous publications. Renowned as a national expert in cardiology, Dr. Oza serves on advisory boards for established companies like Boston Scientific, Johnson and Johnson, GE, and Novo Nordisk, as well as biotech startups. His clinical and business expertise will provide the Acarix team with a fresh new viewpoint of the U.S. market. Dave Braun, a strategic, customer-driven entrepreneur with over four decades of leadership experience, joins Acarix as an advisor. His extensive background in strategic business planning, mergers and acquisitions, banking and investor relations, organization development, and team building will bring a fresh perspective to operational strategies. Adding these three advisors emphasizes Acarix's commitment to driving innovation in cardiac health while expanding its reach in the United States. The new advisory board members will enhance efforts to develop solutions that improve patient outcomes and advance the standard of care in cardiac diagnostics.
공시 • Feb 02Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million. Security Name: Shares Security Type: Common Stock Securities Offered: 181,005,581 Price\Range: SEK 0.186
공시 • Feb 01Acarix AB (publ) Announces CEO ChangesThe Board of Acarix AB (publ) announced the appointment of Aamir Mahmood as new CEO with immediate effect, starting February 1, 2024. Mr. Mahmood succeeds Acting CEO Fred Colen as well as Helen Ljungdahl Round who has decided not to return to her position later in 2024. Aamir Mahmood has more than twenty years of experience in corporate leadership in the medical device industry with a successful track record of Global commercial roles in cardiovascular device markets, including sales, marketing and strategy functions at LivaNova, Boston Scientific, and Merck. Aamir presently serves as General Manager/Vice President Americas of MicroPort CRM. MicroPort is an industry leader in the field of pacemakers and other cardiac devices used for diagnosis, treatment and management of heart rhythm disorders and heart failure. Prior to running the Americas for MicroPort, Aamir rotated through two Ex Pat assignments in Europe running Global Sales followed by Global Marketing & Strategy. Aamir has an MBA and is a member of Young Presidents’ Organization (YPO). Aamir succeeds Helen Ljungdahl Round who was appointed CEO of Acarix in January of 2022. Under Helen’s leadership Acarix established a subsidiary and commercial team in the US market, secured key commercial contracts with the Veterans Affairs Health Administration, published a clinical framework for use of the CADScor System in collaboration with the American College of Cardiology (ACC), and raised growth capital from a broad base of investors to enable further market expansion. Aamir Mahmood assumed the CEO position on February 1, 2024.
공시 • Dec 15+ 5 more updatesAcarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024Acarix AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024
공시 • Nov 24Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare NetworkAcarix AB (publ) announced an advancement in the utilization of its CADScor System within the Veterans Administration (VA) Healthcare network. The Southeast Louisiana VA Healthcare System has reordered CADScor Patches in their Slidell and Baton Rouge locations to be used with the CADScor System for risk-stratification of symptomatic patients suspected of coronary artery disease (CAD) throughout various facilities within their system. The Southeast Louisiana VA Healthcare System was the first VA location to place orders for CADScor System and patches in February, with approval of the CADScor System into their Standard Operating Procedure (SOP) in August. Since integrating the CADScor System into their SOP, the Southeast Louisiana VA Team has also aligned their Computerized Patient Record System (CPRS) with the SOP to ensure all relevant symptomatic patients suspected of CAD undergo a CADScor System Test. In the past few months, the Acarix team has collaborated closely with the Southeast Louisiana VA Leadership Team, providing support to more than 100 Healthcare Professionals (HCPs) through various activities, including CADScor System in-servicing within their Cardiology group. Furthermore, the team has been actively engaged in monthly Primary Care meetings with the Chief of Cardiology, effectively developing awareness about the CADScor System.
공시 • Oct 19Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 90,573,602 Price\Range: SEK 0.6 Transaction Features: Rights Offering
공시 • Aug 29Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical AdvisorAcarix AB (publ) announced the appointment of Dr. Deepak R. Talreja, MD, as new Medical Advisor. With an impressive background in cardiology, Dr. Talreja brings a wealth of knowledge and expertise to Acarix, further strengthening the company's commitment to transforming early cardiac diagnostics through cutting-edge acoustic and AI-based technology. As a highly respected cardiologist expert, Dr. Talreja has been at the forefront of numerous groundbreaking research initiatives, pioneering advancements that have significantly impacted patient care and outcomes. He is a graduate of the University of Virginia School of Medicine, completed his Internship and Residency at Vanderbilt University Medical Center, and fellowship at the Mayo School of Medicine. Dr. Talreja is board certified by the American Board of Internal Medicine (ABIM) in cardiovascular disease, interventional cardiology, and internal medicine: He is currently the Medical Director of the Cardiovascular Service Line at Sentara Health. Dr. Talreja's vast experience and leadership experience in cardiac electrical system procedures, interventional cardiac procedures, heart conditions and overall cardiac patient care align very well with Acarix's mission to develop patient-focused innovative solutions that address some of the challenges in early cardiac healthcare.
공시 • May 12Acarix AB Elects Mikael Thorén as DirectorAcarix AB elected Mikael Thorén as new director at the AGM held on May 11, 2023.
공시 • Feb 17Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023Acarix AB (publ) announced that they will report fiscal year 2022 final results on Apr 20, 2023
공시 • Feb 16+ 3 more updatesAcarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024Acarix AB (publ) announced that they will report Q4, 2023 results on Feb 15, 2024
공시 • Feb 14Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023Acarix AB (publ) announced that they will report Q4, 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023